한글목차

세계의 담관암 시장 규모는 2025년에는 40억 3,000만 달러로 추정되고, 2032년에는 71억 8,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 CAGR 8.6%를 나타낼 것으로 예측됩니다.

그림. 담관암 지역별 시장 점유율(%)(2025년)

담관암은 담도암으로도 알려져 있으며 담관에 생기는 드문 유형의 암입니다. 담관은 간과 담낭을 소장에 연결하는 관입니다. 담관암은 담관에 늘어선 세포에 이상이 생겨 제어 불능으로 증식하여 종양을 형성함으로써 발생합니다. 담관암을 발병하는 주요 위험 인자로는 원발성 경화성 담관염(PSC), 염증성 장 질환, 간 플루크, 담관의 특정 선천적 이상 등이 있습니다. 증상으로는 황달, 가려움증, 복통, 체중 감소, 푸른 흰 대변 등이 있습니다. 진단에는 일반적으로 초음파 검사, CT 스캔, MRI 스캔 등의 이미지 검사 및 생검이 수행됩니다. 치료 옵션은 암의 단계에 따라 다르며 수술, 방사선 요법, 화학 요법, 표적 요법 등이 있습니다. 그러나 담관암은 조기 발견이 어렵고 종양의 증식이 느리기 때문에 생존율이 낮고 예후 불량입니다.

시장 역학 :

세계의 담관암 시장의 성장은 주로 PSC나 간플럭스 감염 등 위험 인자의 유병률 증가가 견인하고 있습니다. 미국 질병관리예방센터(CDC)에 따르면 PSC는 미국에서 약 3만 명이 앓고 있습니다. 담관암의 이해 부족이나 진단의 지연도, 진행기에서의 진단에 연결되어, 그 결과, 시장의 성장을 가속하고 있습니다. 게다가 담관암의 치료 성적을 개선하기 위한 표적 약물 개발을 위한 연구 자금이 증가하고 있는 것도 시장 관계자에게 유리한 기회를 제공할 가능성이 있습니다. 그러나 질병 인지도가 낮고 수술의 복잡성이 시장 성장을 방해할 수 있습니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 담관암 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모 및 연간 평균 성장률(CAGR%)을 제공합니다.
• 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개변수를 바탕으로 세계 담관암 시장에서 주요 기업 프로파일을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대 및 마케팅 전술에 대한 정보를 기반으로 의사 결정을 내릴 수 있습니다.
• 세계의 담관암 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
• 이해관계자는 세계의 담관암 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적 및 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의 및 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제 및 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 주요 발전
• 규제 시나리오
• 인수 및 제휴 시나리오
• 자금 조달 및 투자
• PEST 분석
• Porter's Five Forces 분석

제4장 세계의 담관암 시장 : COVID-19 팬데믹의 영향

• 전체적인 영향
• 정부의 대처
• COVID-19에 의한 시장에 대한 영향

제5장 세계의 담관암 시장 : 치료 유형별(2020-2032년)

• 화학 요법
• 표적 요법
• 면역 요법
• 기타

제6장 세계의 담관암 시장 : 유통 채널별(2020-2032년)

• 원내 약국
• 소매 약국
• 온라인 약국

제7장 세계의 담관암 시장 : 지역별(2020-2032년)

• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제8장 경쟁 구도

• 기업 프로파일
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Johnson &Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Fresenius Kabi AG
  • Mylan NV
  • ConMed Corporation
  • Boston Scientific Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • Incyte Corporation

제9장 분석가 추천

• 운명의 원
• 애널리스트의 견해
• Coherent Opportunity Map(COM)

제10장 참고문헌 및 조사방법

• 참고문헌
• 조사방법

영문목차

Global Bile Duct Cancer Market is estimated to be valued at USD 4.03 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

Figure. Bile Duct Cancer Market Share (%), By Region 2025

Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct is a tube that connects the liver and gallbladder to the small intestine. Bile duct cancer occurs when the cells that line the bile ducts become abnormal and grow uncontrollably, forming a tumor. Key risk factors for developing bile duct cancer include primary sclerosing cholangitis (PSC), an inflammatory bowel disease, liver flukes, and certain congenital abnormalities of the bile ducts. Symptoms may include jaundice, itching, abdominal pain, weight loss, and pale stools. Diagnosis usually involves imaging tests such as ultrasound, CT scan, and MRI scans, as well as biopsy. Treatment options depend on the stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted therapy. However, bile duct cancer has a poor prognosis with low survival rates due to difficulties in early detection and slow growth nature of the tumors.

Market Dynamics:

Global bile duct cancer market growth is primarily driven by increasing prevalence of risk factors such as PSC and liver flukes infections. According to the Center for Disease Control and Prevention (CDC), PSC affects around 30,000 people in the U.S. Insufficient understanding and delays in diagnosing bile duct cancer also contribute to late-stage diagnosis, thus, driving the market growth. Moreover, rising research funding towards targeted drug development for improving the bile duct cancer treatment outcomes can offer lucrative opportunities for market players. However, low disease awareness and complexity in surgical procedures can hamper the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global bile duct cancer market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bile duct cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, and Bristol-Myers Squibb Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market

Detailed Segmentation-

• By Treatment Type
  • Chemotherapy
  • Gemcitabine
  • Cisplatin
  • Oxaliplatin
  • Capecitabine
  • 5 fluorouracil (5-FU)
  • Targeted Therapy
  • Pemigatinib
  • Infigratinib (Phase 3)
  • Ivosidenib (Phase 3)
  • Immunotherapy
  • (Pembrolizumab (Phase 3))

Others

• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hoffmann-La Roche Ltd
  • Sanofi
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Fresenius Kabi AG
  • Mylan N.V.
  • ConMed Corporation
  • Boston Scientific Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • Incyte Corporation

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Bile Duct Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Bile Duct Cancer Market, By Treatment Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Gemcitabine
  • Cisplatin
  • Oxaliplatin
  • Capecitabine
  • 5 fluorouracil (5-FU)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pemigatinib
  • Infigratinib (Phase 3)
  • Ivosidenib (Phase 3)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • (Pembrolizumab (Phase 3)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Bile Duct Cancer Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Bile Duct Cancer Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Celgene Corporation
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Fresenius Kabi AG
  • Mylan N.V.
  • ConMed Corporation
  • Boston Scientific Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • Incyte Corporation

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map
• References and Research Methodology
• References
• Research Methodology
• About us and Sales Contact